Literature DB >> 18344116

Increased mitochondrial oxidative damage and oxidative DNA damage contributes to the neurodegenerative process in sporadic amyotrophic lateral sclerosis.

Takahiko Murata1, Chigumi Ohtsuka, Yasuo Terayama.   

Abstract

To investigate the possibility that mitochondrial oxidative damage or oxidative DNA damage or both contribute to the neurodegenerative process of sporadic amyotrophic lateral sclerosis (sALS), this study used high-performance liquid chromatography with an electrochemical detector to measure the concentrations of the reduced and oxidized forms of coenzyme Q10 (CoQ10) and 8-hydroxy-2'-deoxyguanosine (8-OHdG) in the cerebrospinal fluid (CSF) of 17 patients with sALS and 17 age-matched controls with no neurological diseases. The percentage of oxidized CoQ10 in the CSF of sALS patients was greater than that in the CSF of controls (p<0.002) and was negatively correlated with the duration of illness (rho=-0.61, p<0.01). The concentration of 8-OHdG in the CSF of sALS patients was greater than that in the CSF of controls (p<0.005) and was positively correlated with the duration of illness (rho=0.53, p<0.005). The percentage of oxidized CoQ10 was correlated with the concentrations of 8-OHdG in the CSF of sALS patients (rho=-0.53, p<0.05). These results suggest that both mitochondrial oxidative damage and oxidative DNA damage play important roles in the pathogenesis of sporadic amyotrophic lateral sclerosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18344116     DOI: 10.1080/10715760701877262

Source DB:  PubMed          Journal:  Free Radic Res        ISSN: 1029-2470


  20 in total

1.  Differential protection of black-seed oil on econucleotidase, cholinesterases and aminergic catabolizing enzyme in haloperidol-induced neuronal damage of male rats.

Authors:  Jacob K Akintunde; C Abigail Irechukwu
Journal:  Ther Adv Drug Saf       Date:  2016-07-22

2.  Amyotrophic Lateral Sclerosis Associated with Statin Use: A Disproportionality Analysis of the FDA's Adverse Event Reporting System.

Authors:  Beatrice A Golomb; Abril Verden; Alexis K Messner; Hayley J Koslik; Keith B Hoffman
Journal:  Drug Saf       Date:  2018-04       Impact factor: 5.606

Review 3.  Mitochondria in neurodegeneration.

Authors:  E Lezi; Russell H Swerdlow
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

4.  Dietary lipid unsaturation influences survival and oxidative modifications of an amyotrophic lateral sclerosis model in a gender-specific manner.

Authors:  Daniel Cacabelos; Victoria Ayala; Omar Ramírez-Nunez; Ana Belen Granado-Serrano; Jordi Boada; Jose C E Serrano; Rosanna Cabré; Gisela Nadal-Rey; Maria Josep Bellmunt; Isidro Ferrer; Reinald Pamplona; Manuel Portero-Otin
Journal:  Neuromolecular Med       Date:  2014-07-01       Impact factor: 3.843

Review 5.  Mitochondrial DNA mutation-elicited oxidative stress, oxidative damage, and altered gene expression in cultured cells of patients with MERRF syndrome.

Authors:  Shi-Bei Wu; Yi-Shing Ma; Yu-Ting Wu; Yin-Chiu Chen; Yau-Huei Wei
Journal:  Mol Neurobiol       Date:  2010-04-23       Impact factor: 5.590

Review 6.  Nrf2--a therapeutic target for the treatment of neurodegenerative diseases.

Authors:  Delinda A Johnson; Jeffrey A Johnson
Journal:  Free Radic Biol Med       Date:  2015-08-14       Impact factor: 7.376

7.  Coenzyme Q10 effects in neurodegenerative disease.

Authors:  Meredith Spindler; M Flint Beal; Claire Henchcliffe
Journal:  Neuropsychiatr Dis Treat       Date:  2009-11-16       Impact factor: 2.570

8.  Mitochondrial glutathione transport is a key determinant of neuronal susceptibility to oxidative and nitrosative stress.

Authors:  Heather M Wilkins; Danielle Kirchhof; Evan Manning; Jamie W Joseph; Daniel A Linseman
Journal:  J Biol Chem       Date:  2013-01-02       Impact factor: 5.157

Review 9.  Mitochondrial medicine for neurodegenerative diseases.

Authors:  Heng Du; Shirley ShiDu Yan
Journal:  Int J Biochem Cell Biol       Date:  2010-01-11       Impact factor: 5.085

10.  Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III.

Authors:  Petra Kaufmann; John L P Thompson; Gilberto Levy; Richard Buchsbaum; Jeremy Shefner; Lisa S Krivickas; Jonathan Katz; Yvonne Rollins; Richard J Barohn; Carlayne E Jackson; Ezgi Tiryaki; Catherine Lomen-Hoerth; Carmel Armon; Rup Tandan; Stacy A Rudnicki; Kourosh Rezania; Robert Sufit; Alan Pestronk; Steven P Novella; Terry Heiman-Patterson; Edward J Kasarskis; Erik P Pioro; Jacqueline Montes; Rachel Arbing; Darleen Vecchio; Alexandra Barsdorf; Hiroshi Mitsumoto; Bruce Levin
Journal:  Ann Neurol       Date:  2009-08       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.